Loading stock data…
Ovid Therapeutics Inc. (OVID)
$2.72+0.17 (+6.67%)
After Hours$2.67-0.05 (-1.83%)· Last close Jun 29
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ovid Therapeutics Inc. in the Healthcare sector is trading at $2.72 with a market capitalization of $446M. Wall Street consensus targets $5.47 (9 analysts), implying a +101.1% move over the next 12 months. The stock is currently near its 52-week high of $3.10, remaining 41.7% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +101.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↓ | $718,000↑ | $132,000↓ | $6.27M↑ | $130,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$17.85M↓ | -$12.29M↑ | -$12.52M↓ | -$5.07M↑ | -$12.55M |
| Net Income | -$16.99M↓ | $9.66M↑ | -$12.16M↓ | -$4.68M↑ | -$10.23M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a G...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$446.07M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.18
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.19%
Volume
Today's trading volume
1.52M
Recent News
We're Hopeful That Ovid Therapeutics (NASDAQ:OVID) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Here is Why Ovid Therapeutics (OVID) is One of the Best Fast Growing Penny Stocks
Ovid Therapeutics Inc. (NASDAQ:OVID) is one of the best fast growing penny stocks to buy right now. On April 9, H.C. Wainwright raised the firm’s price target on Ovid Therapeutics to $4 from $2 with a Buy rating on the shares. The company’s OV4071 oral KCC2 candidate is entering the clinic imminently, triggering warrant exercises. […]
Ovid Therapeutics Q4 Earnings Call Highlights
Ovid Therapeutics (NASDAQ:OVID) outlined new pipeline and financing updates alongside its fourth-quarter and full-year 2025 results, highlighting regulatory clearance in Australia for its KCC2 direct activator OV4071, new safety and tolerability data for its seizure candidate OV329, and a $60 millio
Here's Why Ovid Therapeutics Stock Popped Higher Today
Ovid stock surged 18% following positive Phase 1 data for OV329, and investors are getting excited about a forthcoming Phase 2.
Exchange-Traded Funds, Equity Futures Lower Ahead of Key Economic Data, FOMC Meeting
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively tr